← All trials
NCT03930264
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2019
- Primary completion
- Jun 30, 2019
- Completion date
- Jul 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nova Laboratories LimitedLead sponsor
- University of ManchesterOverall official - principal investigator
- Medicines Evaluation Unit LtdCollaborator
- Syne Qua Non LimitedCollaborator
- Diamond Pharma ServicesCollaborator
- Boyd ConsultantsCollaborator
- Black County Pathology ServicesCollaborator
- Alderley AnalyticalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.